We're lowering our price target on Bristol Myers as two key overhangs persist
-
最新报道：Bristol Myers Squibb shares fell 3% after analysts lowered the price target to $50 from $55, citing persistent concerns over patent expirations for key drugs Revlimid and Eliquis. The company faces revenue declines as these blockbuster drugs lose exclusivity, with Revlimid sales expected to drop sharply this year. Management maintains guidance but acknowledges competitive pressures, while analysts remain cautious about the pipeline's ability to offset losses. The stock has underperformed the market, down 15% year-to-date.
下一篇
42-year-old CEO: I turned my hobby into a $50 million-a-year business backed by Ryan Reynolds
- Homage CEO Ben Chan turned his passion for thrifting vintage sports apparel into a success...
24小时热点
财联社10月28日电，苹果据悉计划于周三正式发布14英寸和16英寸两款触屏MacBook。苹果已讨论将其新款14英寸触屏Mac的定价定为2899美元
币界网消息，财联社10月28日电，苹果据悉计划于周三正式发布 ...
82
热点专题
417590